A phase 2, Proof of Concept Trial of AG-348 in Thalassemia.

Trial Profile

A phase 2, Proof of Concept Trial of AG-348 in Thalassemia.

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs AG 348 (Primary)
  • Indications Thalassaemia
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 14 Feb 2018 According to an Agios Pharmaceuticals media release, the company is planning to Initiate this study in fourth quarter of 2018.
    • 12 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top